<DOC>
	<DOCNO>NCT02419755</DOCNO>
	<brief_summary>This study test safety effectiveness add bortezomib vorinostat chemotherapy drug commonly use treat relapse refractory leukemia . Both drug approve Food Drug Administration ( FDA ) treat cancer adult , yet approve tor treatment young patient leukemia . PRIMARY OBJECTIVE - To estimate overall response rate patient MLL rearrange ( MLLr ) hematologic malignancy receive bortezomib vorinostat combination chemotherapy backbone . SECONDARY OBJECTIVES - Estimate event-free overall-survival . - Describe toxicity experience participant treatment . OTHER PRESPECIFIED OBJECTIVES - To identify genomic lesion comprehensive whole genome , exome transcriptome sequencing patient . - To compare minimal residual disease ( MRD ) result three modality : flow cytometry , polymerase chain reaction ( PCR ) deep sequencing .</brief_summary>
	<brief_title>Bortezomib Vorinostat Younger Patients With Refractory Relapsed MLL Rearranged Hematologic Malignancies</brief_title>
	<detailed_description>All participant undergo diagnostic lumbar puncture intrathecal ( IT ) chemotherapy [ Cytarabine , methotrexate , hydrocortisone ( ITMHA ) ] prior cycle 1 . Throughout phase therapy , dexrazoxane give supportive care participant prior receive mitoxantrone doxorubicin . STRATUM 1 : MYELOID MALIGNANCIES : Induction : - Cytarabine , Days 1-5 - Bortezomib , Days 1 , 4 , 8 , 11 , 15 , 18 - Vorinostat , Days 1-4 , 8-11 , 15-18 - ITMHA.for CNS1 , Day 1 - ITMHA CNS 2/3 , Days 1 , 4 , 8 , 11* , 15* , 18* 22* ( * Twice weekly two negative CSF ; CNS3 patient must receive least 6 dos ) - Participants cumulative anthracycline &lt; 460 mg/m2 also receive Mitoxantrone Day 1 - Responders may receive 6 course . ITMHA limit day 1 subsequent course Maintenance ( bridge ) therapy ( 1 cycle stem cell transplant need ) : : - Bortezomib , Days 1 , 4 , 8 , 11 , 15 , 18 - Vorinostat , Days 1-4 , 8-11 , 15-18 - ITMHA , Day 1 STRATUM 2 : Acute Lymphoid Leukemia ( ALL ) Mixed Lineage Malignancies ( MLL ) : Induction : - Mitoxantrone , Day 1 - PEG-L-Asparaginase ( Erwinia L-asparaginase ) , Day 3 - Dexamethasone , Days 1-4 , 8-11 , 15-18 - Bortezomib , Days 1 , 4 , 8 , 11 , 15 , 18 - Vorinostat , Days 1-4 , 8-11 , 15-18 - ITMHA CNS1 , Days 1 , 8 , 15 , 22 - ITMHA CNS2/3 , Days 1 , 4 , 8 , 11 , 15 , 22 - Participants &gt; 460 mg/m2 cumulative anthracyclines receive mitoxantrone Consolidation : - Methotrexate , Days 1 15 - Bortezomib , Days 8 , 11 , 22 , 25 - Vorinostat , Days 8-11 , 22-25 - ITMHA , Days 1 15 Interim Maintenance : - Mercaptopurine , Days 1-42 - Doxorubicin , Days 1 29 - PEG-L-asparaginase ( Erwinia L-asparaginase ) , Days 1 , 15 , 29 - Dexamethasone , Days 8-11 , 22-25 , 36-39 - Bortezomib Days 8,11,22,25,36,39 - Vorinostat , Days 8-11 , 22-25 , 36-39 - ITMHA , Day 1 Reinduction : - Mitoxantrone , Day 1 - PEG-L-asparaginase ( Erwinia L-asparaginase ) , Day 3 - Dexamethasone , Days 1-4 , 8-11 , 15-18 - Bortezomib Days 1 , 4 , 8 , 11 , 15 , 18 - Vorinostat Days 1-4 , 8-11 , 15-18 - IT MHA Day 1 Maintenance ( 12 cycle ) : - Mercaptopurine , Days 1-28 - Methotrexate , Days 8 , 15 , 22 - Dexamethasone , Days 1-4 - Bortezomib , Days 1 4 - Vorinostat , Days 1-4 - ITMHA , Day 1 Bridge Therapy ( 1 cycle stem cell transplant need ) : - Bortezomib , Days 1 , 4 , 8 , 11 , 15 , 18 - Vorinostat , Days 1-4 , 8-11 , 15-18 - Dexamethasone , Days 1-4 , 8-11 , 15-18 - ITMHA , Day 1</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>INCLUSION CRITERIA : Age : Patient ≤ 21 year age ( i.e. , eligible 22nd birthday ) . Diagnosis : Participant hematologic malignancy positive MLLr determine fluorescent situ hybridization ( FISH ) RTPCR , disease meet least one follow criterion : Relapsed refractory chemotherapy Relapsed hematopoietic stem cell transplantation ( HSCT ) Relapsed refractory secondary leukemia ( Relapse define reappearance leukemia cell attainment complete remission refractory define ≥5 % blast end induction . Patients achieve MRD negative status follow reappearance blast less 5 % eligible . ) Patients must verification malignancy relapse , include immunophenotyping , confirm diagnosis . Performance Level : Karnofsky ≥50 % patient &gt; 16 year age Lansky ≥50 patient ≤16 year age ( See Appendix III ) . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Prior therapy : Patients relapse receive standard ALL maintenance chemotherapy consist daily 6MP , weekly methotrexate , monthly vincristine , monthly steroid pulse require wait period entry onto study . Patients relapse therapy standard ALL maintenance therapy must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . Cytotoxic therapy : At least 14 day since completion cytotoxic therapy exception hydroxyurea , low dose cytarabine , intrathecal chemotherapy permit 24 hour prior start protocol therapy . For patient aggressive disease peripheral blood rising , 14 day washout period may omit . Biologic ( antineoplastic ) agent : At least 7 day since completion therapy biologic agent donor lymphocyte infusion ( DLI ) . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . Stem cell transplant rescue : ≥2 month must elapse since time transplant . Patients active graftvshost disease ( GVHD ) eligible . Organ function requirement : All patient must : Adequate renal function define : Creatinine clearance radioisotope GFR ≥70 mL/min/1.73 m^2 , OR adequate serum creatinine base age/gender . Adequate liver function define : Total bilirubin ≤ ULN age , total bilirubin &gt; ULN , direct bilirubin ≤ 1.4 mg/dL , AND SGPT ( ALT ) ≤4 x ULN age , unless elevation due leukemic infiltration Adequate cardiac function define : Shortening fraction ≥27 % echocardiogram OR Ejection fraction ≥50 % gate radionuclide study Central nervous system ( CNS ) function define : Patients seizure disorder may enrol allow anticonvulsant well control . Benzodiazepines gabapentin acceptable . CNS toxicity ≤ Grade 2 . Adequate pulmonary function define FVC &gt; 50 % predict OR , unable perform pulmonary function testing , must maintain pulse oximetry oxygen saturation &gt; 92 % room air . EXCLUSION CRITERIA : Patients require anticonvulsant know activate cytochrome p450 system , particular anticonvulsant phenytoin , carbamazepine , phenobarbital , eligible . Benzodiazepines gabapentin acceptable . Please see Appendix I list drug know potent inducers/inhibitors cytochrome p450 system Appendix II list anticonvulsant base CYP3A4/5 enzyme induction . ALL patient receive asparaginase product ( E. Coli , PEGasparaginase , Erwinia asparaginase ) study ( eg , due prior severe pancreatitis , stroke toxicity ) eligible . Patients clinically significant prior allergy PEGasparaginase eligible Erwinia Lasparaginase substitute . Pregnancy breast feeding : patient pregnant breastfeed eligible study yet available information regard human fetal teratogenic toxicity . Negative pregnancy test must obtain girl postmenarchal . Males female reproductive potential may participate unless agree use effective birth control method . Investigational drug : Patients currently receive another investigational drug eligible . Anticancer agent : Patients currently receive anticancer agent exception delineate eligibility criterion . Infection : Patients uncontrolled infection eligible . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . Known human immunodeficiency virus ( HIV ) infection ( prestudy testing require ) . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , study participation , follow , interpretation study research . Patients Fanconi anemia , Kostmann syndrome , Shwachman syndrome , inherit bone marrow failure syndromes eligible . Patients opinion investigator may able comply safety monitoring requirement study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Infant leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>Biphenotypic leukemia</keyword>
	<keyword>Pediatric</keyword>
</DOC>